Research-for-Cure Academy

Aubin Nanfack

Nationality: Cameroonian
Institution: Chantal Biya International Reference Center (CIRCB)
Country of work: Cameroon

What is your motivation for engaging in HIV cure and remission research?

Antiretroviral treatment (ART), even successful, remains a lifelong treatment and its sustainability presents significant challenges. Therefore, underscoring the need to develop strategies for elimination or control of HIV through functional cure or ideally complete viral eradication. HIV cure and remission research brings hope for ending HIV/AIDS through novel approaches and offers a unique chance to address this very important challenge. I strongly believe that concerted global efforts from researchers of various fields will result in successful cross-clade strategy, including HIV-1 CRF02_AG, which is the most prevalent subtype in Cameroon.

What is your current area of research?

I currently lead the laboratory of immunology and microbiology in my institution, we are actively involved in studies focusing on neutralizing antibodies (breath and potency) and envelope binding patterns in HIV-1 CRF02_AG infected individuals. We are also working on the development, validation and standardization of a simple and affordable assay to detect most frequent HIV drug resistance mutations affecting first-line ART in resource constrained settings using dried blood spot samples.